Screener
CRISPR Therapeutics CRSP EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from CRISPR Therapeutics’s reported figures.
The source filing: CRISPR Therapeutics’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:48 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204188
FAQ
- What is CRISPR Therapeutics's EBITDA?
- CRISPR Therapeutics (CRSP) reported EBITDA of -$125.93M in Q1 2026.
- How has CRISPR Therapeutics's EBITDA changed year-over-year?
- CRISPR Therapeutics's EBITDA increased by 12.4% year-over-year, from -$143.69M to -$125.93M.
- What is the long-term trend for CRISPR Therapeutics's EBITDA?
- Over 2 years (2022 to 2025), CRISPR Therapeutics's EBITDA has grown at a -0.3% compound annual growth rate (CAGR), from -$648.99M to -$645.09M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about CRISPR Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude